drugset / Trial / NCT02725177

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT02725177

NaSingle-groupOpen-labelTreatment

Summary

Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)

Timeline

Start
2016-07
Primary completion
2021-12
Completion
2022-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Acthar Peptide 80 iu